We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$10.2B
1-Year Est. Return
149.19%
This Fund
S&P 500
This Quarter
Est. Return
+9.22%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$10.2B
AUM Growth
-$22.3M
(-0.22%)
Cap. Flow
-$444M
Cap. Flow
% of AUM
-4.38%
Top 10 Holdings %
Top 10 Hldgs %
76.54%
Holding
36
New
3
Increased
9
Reduced
7
Closed
6
Top Buys
| 1 |
Cytokinetics
CYTK
|
+$212M |
| 2 |
DMRA
Damora Therapeutics
DMRA
|
+$97.2M |
| 3 |
TERN
Terns Pharmaceuticals
TERN
|
+$55.2M |
| 4 |
Celcuity
CELC
|
+$28.8M |
| 5 |
Avalo Therapeutics
AVTX
|
+$22M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$393M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$256M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$79.9M |
| 4 |
PTC Therapeutics
PTCT
|
+$52M |
| 5 |
ORKA
Oruka Therapeutics
ORKA
|
+$40.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$22.7B
| $1.56B | 15.36% |
2,630,000
+23,940
| +0.9% | +$11.9M |
|
2
Ascendis Pharma A/S
ASND
$17.4B
| $1.16B | 11.41% |
5,062,500
-48,611
| -1% | -$10.9M |
|
3
Madrigal Pharmaceuticals
MDGL
$12.2B
| $952M | 9.38% |
1,818,181
+10,681
| +0.6% | +$5.1M |
|
4
Krystal Biotech
KRYS
$10.7B
| $746M | 7.35% |
2,888,888
| – | – |
|
5
argenx
ARGX
$54.5B
| $730M | 7.19% |
1,000,000
+10,000
| +1% | +$7.83M |
|
6
Arrowhead Research
ARWR
$10.4B
| $671M | 6.61% |
10,699,999
+74,999
| +0.7% | +$4.75M |
|
7
Kymera Therapeutics
KYMR
$9.08B
| $623M | 6.13% |
7,474,747
| – | – |
|
|
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
| $492M | 4.84% |
12,222,222
| – | – |
|
|
CNTA
9
DELISTED
Centessa Pharmaceuticals
CNTA
| $454M | 4.47% |
11,430,455
-3,125,100
| -21% | -$79.9M |
|
|
10
Celcuity
CELC
$5.06B
| $385M | 3.79% |
3,375,000
+263,889
| +8% | +$28.8M |
|
11
Xenon Pharmaceuticals
XENE
$6.55B
| $336M | 3.31% |
5,777,777
+353,333
| +7% | +$16.3M |
|
12
Structure Therapeutics
GPCR
$3.67B
| $316M | 3.11% |
6,555,555
| – | – |
|
|
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
| $300M | 2.96% |
5,695,000
+1,345,000
| +31% | +$55.2M |
|
14
Vera Therapeutics
VERA
$2.98B
| $237M | 2.33% |
5,888,888
| – | – |
|
15
Revolution Medicines
RVMD
$39.1B
| $228M | 2.25% |
2,344,444
+174,444
| +8% | +$17.6M |
|
|
16
Cytokinetics
CYTK
$11.2B
| $220M | 2.16% |
+3,333,333
| New | +$212M |
|
17
Ocular Therapeutix
OCUL
$2.16B
| $104M | 1.03% |
12,315,000
+1,537,223
| +14% | +$14.7M |
|
|
DMRA
18
Damora Therapeutics
DMRA
$1.72B
| $98M | 0.97% |
+3,783,000
| New | +$97.2M |
|
19
uniQure
QURE
$2.83B
| $97.4M | 0.96% |
5,959,595
-190,405
| -3% | -$3.86M |
|
20
Taysha Gene Therapies
TSHA
$1.55B
| $97M | 0.96% |
21,700,000
| – | – |
|
|
DFTX
21
Definium Therapeutics
DFTX
$5.79B
| $94.5M | 0.93% |
5,000,000
| – | – |
|
|
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
| $77M | 0.76% |
2,300,000
-600,000
| -21% | -$23.5M |
|
23
Alkermes
ALKS
$8.65B
| $42.4M | 0.42% |
1,200,000
-200,000
| -14% | -$6.2M |
|
|
SEPN
24
Septerna Inc
SEPN
$1.55B
| $32.1M | 0.32% |
1,337,500
| – | – |
|
25
Viridian Therapeutics
VRDN
$2.1B
| $29.3M | 0.29% |
1,500,000
| – | – |
|
Similar funds
GI
IIM
RA
GT
VPIM
OIA
ECM
BEI